Jardiance Mechanism of Action: Effects on Kidneys and Heart

Jardiance (empagliflozin) works by blocking a protein in the kidneys called SGLT2, which is responsible for pulling glucose back into the bloodstream after the kidneys filter it out. With that transporter shut down, glucose stays in the urine instead of being reabsorbed, lowering blood sugar. But this simple-sounding action triggers a cascade of downstream effects on the heart, blood vessels, and kidney tissue that go well beyond glucose control, which is why the drug is now prescribed for heart failure and chronic kidney disease in people who don’t even have diabetes.

The Primary Target in the Kidney

Your kidneys filter roughly 180 grams of glucose out of the blood each day. Under normal circumstances, almost all of it gets reabsorbed before it reaches the bladder. The protein doing most of that work is sodium-glucose cotransporter 2, or SGLT2, which sits in the early stretch of the kidney’s filtering tubes (the proximal tubule). SGLT2 handles about 90 percent of glucose reabsorption; a second transporter, SGLT1, picks up the rest further downstream.

Jardiance binds to SGLT2 with very high selectivity, roughly 2,700-fold greater affinity for SGLT2 than for SGLT1.¹ That selectivity matters because SGLT1 also operates in the gut, where it helps absorb dietary glucose. By leaving SGLT1 largely alone, Jardiance avoids much of the gastrointestinal trouble that a less selective blocker might cause. Once SGLT2 is inhibited, a meaningful amount of glucose spills into the urine each day, taking calories with it.²

How It Protects the Kidneys

The glucose-lowering action is the part most people hear about, but the kidney protection story is arguably more interesting. SGLT2 doesn’t just carry glucose; it co-transports sodium. When Jardiance blocks this transporter, extra sodium and glucose flow past the proximal tubule and reach a downstream sensor called the macula densa. This sensor detects the higher sodium and chloride delivery and triggers a reflex known as tubuloglomerular feedback, which constricts the tiny artery feeding blood into the kidney’s filtering unit (the glomerulus).³

The result is a drop in the pressure inside each glomerulus. In diabetes and chronic kidney disease, that pressure is often abnormally high, a state called hyperfiltration that gradually wears out the filtering membrane. By dialing it back, Jardiance reduces the mechanical stress on the kidney’s filtering surface.⁴ In animal models, this activation of tubuloglomerular feedback is dose-dependent: higher doses of empagliflozin produced greater increases in urinary adenosine, a marker that the feedback loop is actually firing.⁵

There’s a practical wrinkle here that trips people up. When you first start Jardiance, your estimated kidney filtration rate (eGFR) often dips slightly. This can look alarming on a lab report, but it reflects the intended reduction in hyperfiltration, not actual kidney damage. Over months, eGFR stabilizes and the long-term trajectory is better preserved compared to people not on the drug. A large comparative effectiveness study showed that empagliflozin reduced the risk of major kidney events across a wide range of kidney function, including in people whose eGFR was already as low as 30.⁶

Beyond the pressure relief, there’s evidence that blocking SGLT2-mediated glucose entry into proximal tubule cells reduces harmful signaling inside those cells. Lab work on human kidney cells showed that knocking out SGLT2 reversed high-glucose-driven changes linked to inflammation, oxygen-sensing disruption, and scarring.⁷ The kidney’s inner tissue is already operating under tight oxygen margins, so anything that reduces metabolic stress there can help preserve function over time.

Blood Pressure and Fluid Balance

Because Jardiance causes the kidneys to excrete extra glucose and sodium, it produces a mild diuretic effect through two overlapping mechanisms: osmotic diuresis (glucose in the urine pulls water along) and natriuresis (sodium loss drags water with it).⁸ The net result is a reduction in plasma volume and extracellular fluid, which lowers blood pressure without requiring an additional blood pressure pill. In a crossover trial, empagliflozin also reduced arterial stiffness and sympathetic nervous system activity, suggesting its blood pressure effects aren’t purely about fluid removal.⁹

Clinically, these changes show up fast. In heart failure patients studied after about a month on the drug, systolic blood pressure dropped from a median of 130 mmHg to about 117, and peripheral vascular resistance fell significantly.¹⁰ The same study found reductions in left atrial volume and pulmonary artery pressure, signs that the heart was dealing with less congestion. Modest weight loss accompanied these changes, largely attributable to the calorie deficit from glucose lost in the urine and a shift toward burning fat for energy.¹¹

Direct Effects on the Heart

One of the most debated questions about Jardiance is whether its heart benefits are just a downstream consequence of lighter fluid loads and lower blood pressure, or whether the drug acts directly on heart cells. A growing body of lab evidence points to direct cardiac effects, particularly involving a protein called sodium-hydrogen exchanger 1 (NHE1).

NHE1 sits on the surface of heart cells and swaps hydrogen ions out of the cell for sodium ions coming in. When NHE1 is overactive, as it often is in failing hearts, sodium builds up inside the cell. This excess sodium impairs the cell’s ability to pump calcium out, leading to calcium overload, which stiffens the heart muscle and promotes dysfunction.¹² Empagliflozin appears to inhibit NHE1 directly, and a striking finding in mice showed that this benefit persisted even in animals genetically engineered to lack the SGLT2 transporter entirely, confirming that the cardiac effect is independent of the kidney mechanism.¹³

By keeping NHE1 in check, empagliflozin also quiets downstream calcium-related trouble in cardiac fibroblasts, the cells that lay down scar tissue in a damaged heart. Lab experiments showed that empagliflozin-treated fibroblasts had less calcium leaking from their internal stores and lower activity in the signaling pathway that drives them to produce collagen.¹⁴ The practical upshot is less scarring in the heart wall, which helps the muscle stay flexible and pump efficiently.

Switching the Heart’s Fuel Source

A healthy heart is a metabolic omnivore, burning a mix of fatty acids, glucose, and other fuels. In heart failure, this flexibility breaks down and the heart often becomes overly dependent on glucose, a less efficient energy source under the conditions of a struggling heart. Jardiance appears to reset that metabolic balance.

In a pig model of nondiabetic heart failure, empagliflozin shifted the heart away from glucose toward ketone bodies, fatty acids, and branched-chain amino acids. This fuel switch came with a measurable increase in cardiac ATP content and better work efficiency.¹⁵ A study in isolated rat hearts confirmed that the preference for ketone utilization over glucose occurred even when both fuels were equally available, suggesting empagliflozin directly reprograms the heart’s metabolic machinery rather than just changing what fuels are floating around in the bloodstream.¹⁶

This matters particularly during oxygen-poor conditions. When a heart is starved for blood flow and then reperfused, the fuel it was burning before determines how well it bounces back. Ketone bodies generate ATP more efficiently per unit of oxygen consumed, so a heart already primed to use them recovers function better after a period of reduced blood supply.

Tamping Down Inflammation and Scarring

Chronic low-grade inflammation is a constant companion of both heart failure and diabetic kidney disease. It drives tissue scarring, stiffens blood vessels, and worsens pump function over time. Jardiance appears to interfere with several inflammatory pathways that fuel this cycle.

One of the best-studied targets is the NLRP3 inflammasome, a protein complex inside cells that acts like an alarm switch for inflammation. In mouse models of heart failure (both with reduced and preserved pump function), empagliflozin dialed down NLRP3 activation and lowered markers of sterile inflammation in heart tissue, and these were nondiabetic animals.¹⁷ Separate work in mice treated with a cardiotoxic chemotherapy drug showed that empagliflozin reduced expression of several pro-inflammatory proteins across the heart, liver, and kidneys simultaneously.¹⁸

Reviews of the anti-fibrotic evidence have tied these effects to activation of an energy-sensing enzyme called AMPK, reduced oxidative stress, and inhibition of several scarring pathways, and have noted that some of these actions don’t depend on SGLT2 inhibition at all but instead involve other molecular targets on the cell surface.¹⁹ This is a recurring theme with Jardiance: the drug’s benefits extend beyond what you’d predict from blocking a kidney glucose transporter alone.

Effects on Red Blood Cells and Iron

One of the more surprising findings from the large EMPEROR clinical trials involves red blood cell production. Within 12 weeks, empagliflozin raised hemoglobin levels by about 0.6 to 0.9 g/dL compared to placebo.²⁰ That’s a meaningful bump, especially in heart failure patients who are often mildly anemic.

The mechanism appears to involve the kidney’s oxygen-sensing apparatus. As Jardiance reduces the kidney’s workload (less glucose to reabsorb means less oxygen consumed by tubular cells), the relative improvement in kidney oxygenation signals the body to ramp up erythropoietin production, the hormone that tells bone marrow to make more red blood cells. In the EMPEROR data, empagliflozin boosted erythropoietin, increased levels of erythroferrone (a hormone released by developing red cells), and lowered hepcidin, the gatekeeper protein that locks iron away in storage. The net effect was more iron being freed up and shuttled to the bone marrow for hemoglobin production.²¹ For heart failure patients, more oxygen-carrying capacity in the blood can translate to better exercise tolerance and fewer symptoms of fatigue.

Uric Acid Lowering

People with diabetes and heart failure often have elevated uric acid, which is linked to gout, kidney stones, and possibly cardiovascular risk in its own right. Jardiance lowers serum uric acid, and the mechanism ties back to the glucose sitting in the urine. A transporter in the kidney’s collecting duct called GLUT9 normally swaps glucose for uric acid: it pulls glucose into the cell and sends uric acid back into the bloodstream. When Jardiance floods the collecting duct with extra glucose, GLUT9 preferentially reabsorbs glucose and leaves uric acid behind to be flushed out in the urine.²² It’s an elegant side benefit that falls directly out of the drug’s primary kidney action.

Reducing Cardiac Enlargement

Over time, a heart working against high pressures or managing excess fluid volume physically enlarges. This hypertrophy might seem adaptive at first, but eventually the thickened muscle becomes stiff, poorly supplied with blood, and prone to rhythm problems. In mice with hypertrophic heart failure, empagliflozin reduced left ventricular enlargement. Part of this appears to be a simple consequence of lower loading conditions on the heart, but the researchers also identified a specific inflammatory receptor whose upregulation was blunted by the drug, suggesting the anti-hypertrophic effect isn’t purely hemodynamic.²³

Vascular Protection Beyond Blood Pressure

Blood vessel walls are lined with a delicate sugar-protein mesh called the endothelial glycocalyx, which helps regulate fluid exchange, prevent clotting, and relay signals about blood flow. Inflammation strips this coating away, leaving the vessel wall more exposed and less able to dilate properly. Recent work found that empagliflozin preserved this glycocalyx layer in inflamed blood vessels and restored the ability of the endothelium to relax in response to signals, while also improving the nanoscale stiffness of endothelial cells under both inflammatory and diabetic conditions.²⁴ This is still early-stage research, but it adds to the picture of a drug whose vascular effects extend well past simple fluid drainage.

Side Effects That Stem Directly from the Mechanism

Most of Jardiance’s common side effects are predictable once you understand how it works. The glucose-rich urine creates a more hospitable environment for yeast, which is why genital fungal infections are the most frequently reported issue, particularly in women.²⁵ These infections are usually mild and treatable, but they can be recurrent in some people.

The fluid loss that benefits blood pressure and congestion can also cause dehydration and low blood pressure, especially in older adults or anyone already on diuretics. Some degree of adjustment in other medications is common when Jardiance is started.

A rarer but more serious concern is euglycemic diabetic ketoacidosis, a condition where ketone levels rise to dangerous levels even though blood sugar looks normal or only mildly elevated. Because Jardiance lowers blood sugar by dumping it in the urine while simultaneously promoting fat breakdown and ketone production, people under physiological stress (surgery, severe illness, prolonged fasting) can occasionally tip into ketoacidosis without the usual warning signal of very high blood glucose. This is uncommon but important to recognize, because the normal blood sugar reading can delay diagnosis.

An Unsettled Question About the Sympathetic Nervous System

Several lines of evidence have suggested that Jardiance might calm overactive sympathetic nerve signaling, the “fight or flight” system that drives up heart rate, constricts blood vessels, and worsens heart failure over time. One crossover trial did find reduced sympathetic nervous system activity alongside blood pressure lowering.²⁶ But a more recent study using direct measurements of norepinephrine spillover from the heart, kidneys, and whole body found no significant change after 12 weeks of empagliflozin compared with placebo.²⁷ This is a good reminder that the mechanistic story around Jardiance is still being written. Some pathways that look important in animal models or indirect measurements don’t always hold up when tested more rigorously in humans. It doesn’t mean the cardiovascular benefits aren’t real; the clinical trial outcomes are robust. It means scientists are still sorting out exactly which pathways matter most, and which are bystanders.